Casa Grande

Researchers are evaluating the effectiveness of trastuzumab deruxtecan (T-DXd) in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors in the United States. The study focuses on patients who have already received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options. This observational study aims to capture real-world outcomes in a diverse patient population excluding those with breast, colorectal, non-small cell lung, gastric/gastroesophageal junction cancers, and hematological malignancies. Participants will receive trastuzumab deruxtecan monotherapy as prescribed in routine clinical practice following the FDA label. The study will be conducted across approximately 30 sites including community oncology practices, hospital systems, and academic medical centers, enrolling about 100 patients. Treatment will be observed in a real-world setting without intervention on dosing or administration by the study team. During the study, researchers will collect information on tumor response rates and how long patients respond to treatment, following participants for up to 2.5 years after enrollment. Additional outcomes include time to stopping treatment and time to starting subsequent treatments. Data will be gathered from medical records and clinical assessments to understand the treatment’s impact in everyday clinical use, ensuring thorough safety and effectiveness monitoring throughout the study period.